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Abstract
PURPOSE: Chemotherapeutic agents that have shown improved patient outcome when combined with anti–vascular
endothelial growth factor (VEGF) therapy were recently identified to induce the mobilization of proangiogenic Tie-2–
expressingmonocytes (TEMs) and endothelial progenitor cells (EPCs) by platelet release of stromal cell–derived factor
1α (SDF-1α). VEGF blockade was found to counteract cell mobilization. We aimed to determine why agents like gem-
citabine do not elicit TEM and EPC recruitment and may therefore lack synergy with anti-VEGF therapy. EXPERIMEN-
TAL DESIGN: Locally advanced pancreatic cancer patients (n = 20) were monitored during 16 weeks of neoadjuvant
therapy. Treatment was based on gemcitabine with or without the addition of bevacizumab. Blood levels of proangio-
genic cell populations and angiogenesis factors were determined in 2-week intervals. RESULTS: The lack of EPC mo-
bilization during gemcitabine therapy was associated with severe thrombocytopenia and reduced SDF-1α blood
concentrations. Furthermore, myelosuppression by gemcitabine correlated significantly with loss of TEMs. With re-
spect to angiogenic factors stored and released by platelets, plasma levels of the angiogenesis inhibitor thrombo-
spondin 1 (TSP-1) were selectively decreased and correlated significantly with thrombocytopenia in response to
gemcitabine therapy. CONCLUSIONS: A thorough literature screen identified thrombocytopenia as a common feature
of chemotherapeutic agents that lack synergy with anti-VEGF treatment. Our results on gemcitabine therapy indicate
that myelosuppression (in particular, with respect to thrombocytes andmonocytes) interferes with the mobilization of
proangiogenic cell types targeted by bevacizumab and may further counteract antiangiogenic therapy by substan-
tially reducing the angiogenesis inhibitor TSP-1.
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Introduction
Because access to the systemic blood flow is essential for neoplastic
growth and metastasis, the inhibition of vessel formation through
antiangiogenic drugs has become an attractive target in cancer ther-
apy [1,2]. In this context, bevacizumab, a neutralizing monoclonal
antibody to proangiogenic vascular endothelial growth factor (VEGF),
has shown benefit as single agent or in combination with standard che-
motherapy in various types of cancers [3]. Comprehensive phase 3
trials have documented that patients with metastatic breast cancer,
colorectal cancer, or non–small cell lung cancer (NSCLC) profit from
the addition of bevacizumab to chemotherapy [4–6]. However, several
studies failed to detect benefits in overall survival (OS), progression-
free survival (PFS), or objective response rate. For example, patients with
pancreatic cancer receiving antiangiogenic therapy with bevacizumab
showed negligible therapeutic improvements [7–9].
Abbreviations: ELISA, enzyme-linked immunosorbent assay; EPC, endothelial progen-
itor cell; bFGF, basic fibroblast growth factor; 5-FU, 5′-fluorouracil; PD-ECGF, platelet-
derived endothelial cell growth factor; SDF-1α, stromal cell–derived factor 1α; TEM,
Tie-2–expressing monocyte; TSP-1, thrombospondin 1; VEGF, vascular endothelial
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Despite the general dependence of neoplastic growth on neovascu-
larization, the variance in bevacizumab efficacy may arise from biologic
differences among tumor types. Thus, angiogenesis in neoplastic en-
tities “nonresponsive” to bevacizumab might be sustained by factors
other than VEGF. A change in balance by the induction of proangio-
genic mediators such as basic fibroblast growth factor (bFGF) and
platelet-derived endothelial cell growth factor (PD-ECGF) or the
down-regulation of angiogenesis inhibitors like thrombospondin 1
(TSP-1) might promote neovessel formation [10]. However, pancre-
atic cancer patients were found to exhibit increased VEGF serum
and tissue levels, which correlated with advanced stage, postoperative
recurrence, metastasis, and prognosis of these patients [11,12]. Fur-
thermore, inhibition of VEGF potently suppressed pancreatic tumor
growth in several preclinical models thus arguing for a central role
of VEGF in pancreatic cancer [13,14].
In addition to differences in cancer biology, it has been proposed
that the choice of chemotherapy might determine the efficacy of anti-
VEGF treatment [15]. Of note, striking therapeutic improvements
by bevacizumab coadministration were observed for combination
therapy with paclitaxel in metastatic breast cancer, 5′-fluorouracil
(5-FU) and irinotecan in colorectal cancer as well as for paclitaxel
and carboplatin in NSCLC [4–6]. In contrast, the combination of
bevacizumab with gemcitabine as applied for pancreatic cancer was
of minimal benefit [8,9]. Shaked et al. [15] were the first to investi-
gate in a preclinical model whether selected chemotherapeutics have
a substantial impact on the effectiveness of anti-VEGF treatment.
They found that compounds differed significantly in the mobiliza-
tion of proangiogenic endothelial progenitor cells (EPCs) and Tie-
2–expressing monocytes (TEMs). An increase in circulating EPCs
and TEMs was induced within 4 to 24 hours of paclitaxel, docetaxel,
or 5-FU administration and was reflected in enhanced tumor infil-
tration by EPCs and TEMs. In contrast, chemotherapeutics such as
gemcitabine or doxorubicin had no promoting effect on EPC or
TEM recruitment. Importantly, treatment with a VEGF receptor
antibody potently blocked this recruitment thereby blunting the
“proangiogenic adverse effect” of chemotherapy. As a result, the ad-
dition of anti-VEGF therapy to paclitaxel caused enhanced suppres-
sion of tumor growth, whereas the combination with gemcitabine
did not improve antitumor activity.
EPC mobilization was found to be central to the efficacy of com-
bination treatments and seemed to be mediated by the release of stro-
mal cell–derived factor 1α (SDF-1α) in response to chemotherapy.
Corresponding to the growing evidence that megakaryocytes and
platelets are the major sources of SDF-1α [16,17], the increase in
SDF-1α plasma levels after paclitaxel administration was accompa-
nied by a decrease of intracellular SDF-1α stored in platelets. No
substantial changes in SDF-1α levels were observed after gemcitabine
treatment. Therefore, the authors concluded that paclitaxel (as op-
posed to gemcitabine) induces EPC mobilization by prompting plate-
lets to release SDF-1α.
The conclusions of the preclinical study were further strengthened
by clinical data. A significant increase of EPCs and circulating SDF-
1α was found in cancer patients within 4 hours of a single dose of
taxane-based chemotherapy, whereas gemcitabine, doxorubicin, or
cisplatin failed to induce proangiogenic cell recruitment [15,18].
In view of these findings, we focused on the systemic effects of a
“nonresponsive” chemotherapeutic compound to further explain the
lack of EPC and TEM mobilization. In the context of a clinical trial,
locally advanced pancreatic cancer patients received neoadjuvant
gemcitabine treatment with or without bevacizumab coadministration.
We closely monitored soluble angiogenic factors and angiogenesis as-
sociated cell populations to obtain a detailed picture of the effects on
the angiogenic balance by the chemotherapeutic regimen that had
shown unfavorable outcome in combination with bevacizumab. In-
triguingly, the myelosuppressive effect of gemcitabine resulting in
thrombocytopenia correlated with severe changes in angiogenic factors,
which may explain the failure of the combined anti-VEGF therapy.
Materials and Methods
Study Design and Patient Collective
Twenty previously untreated patients with locally advanced non-
metastatic pancreatic cancer (T4, stage III) were enrolled in the study.
Exclusion criteria comprised stage IA to IIB and stage IV disease,
any previous systemic cancer treatment, major surgery within the last
28 days, a history of bleeding or coagulation disorders, as well as other
malignant diseases within the last 5 years.
Patients were randomly assigned to two treatment arms. Both
groups received 1000 mg/m2 gemcitabine on days 1, 8, and 15 of four
consecutive 4-week cycles. Group 1 (four women and five men of me-
dian age 65 years, ranging from 43 to 77 years) started with the bi-
weekly addition of 5 mg/kg bevacizumab in week 3 of the second
cycle. Patients in group 2 (five women and six men of median age
62 years, ranging from 52 to 80 years) received bevacizumab from
the beginning of chemotherapy. The fourth cycle did not include
bevacizumab, providing a gap of at least 8 weeks between the last
antibody dose and pancreatic surgery. Blood samples for monitoring
angiogenesis parameters were drawn from patients at 2-week inter-
vals during the entire neoadjuvant treatment period. CA 19-9 tumor
marker levels were determined by routine hospital analysis.
The clinical study was registered in the public trial registry EudraCT
(no. 2005-004519-32). The study protocol and the analysis of blood
samples were approved by the institutional ethics committee; all pa-
tients gave written informed consent.
Quantification of Angiogenic Factors
Blood was drawn into prechilled tubes containing citrate, theoph-
ylline, adenosine, and dipyridamole; was immediately placed on ice;
and further processed within 30 minutes. After an initial centrifuga-
tion step at 1000g and 4°C for 10 minutes, the plasma superna-
tant was subjected to further centrifugation at 10,000g and 4°C for
10 minutes (to remove remaining platelets). Plasma samples were
analyzed by enzyme-linked immunosorbent assay (ELISA) for con-
centrations of angiogenesis factors. Commercially available ELISA
tests were applied for bFGF, TSP-1, SDF-1α (Quantikine; R&D
Systems, Minneapolis, MN), and for VEGF-A (Quantikine; R&D
Systems or Invitrogen Corp, Camarillo, CA), according to the man-
ufacturers’ instructions. A comparable “sandwich” ELISA system for
PD-ECGF (detection range = 1–100 ng/ml) has previously been re-
ported by us [19,20].
Quantification of EPCs and TEMs
Blood was drawn in EDTA tubes and subjected to staining with an ap-
propriate set of antibodies for evaluation of TEMs (anti-human CD14-
FITC, CD16-PC5, Tie2-PE) and EPCs (anti-human CD3-PC5,
CD19-PC5, CD33-PC5, CD31-FITC, CD34-ECD, CD133-PE, and
the viability stain 7-aminoactinomycin D). Following a “lyse-no-wash”
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procedure with VersaLyse reagent (Immunotech, Beckman Coulter, Brea,
CA) samples were analyzed with an FC500 flow cytometer (Beckman
Coulter) for detection of viable endothelial progenitors (CD3−, CD19−,
CD33−, CD34+, CD133+) and TEMs (CD14+, CD16+, Tie2+).
Evaluation of Response
Objective tumor response to neoadjuvant treatment was evaluated
by computed tomography or magnetic resonance imaging and was
defined in categories of progressive disease, stable disease, or partial
remission according to Response Evaluation Criteria in Solid Tumors
(RECIST). OS of patients was assessed in a 2-year follow-up period
(with one patient alive at the time of study closure).
Statistical Analysis
Statistical analyses were carried out with SPSS 17.0.1 Software
(SPSS, Inc, Chicago, IL) and were based on nonparametric tests
(Spearman, Mann-Whitney U , and Wilcoxon test). Data are gener-
ally presented by box plot illustration; outliers and extreme values are
not depicted.
Results
Bevacizumab Induces VEGF Feedback Production but
Does Not Enhance Tumor Marker Reduction in Response
to Chemotherapy
From August 2006 to September 2008, 20 patients with locally
advanced pancreatic cancer were randomized into two treatment
arms. Both study groups received neoadjuvant gemcitabine therapy
on days 1, 8, and 15 of four consecutive 4-week cycles. Group 2
received biweekly addition of bevacizumab from treatment start,
whereas group 1 had a delayed onset of bevacizumab therapy in week
3 of cycle 2. Blood samples were collected at 2-week intervals during
the neoadjuvant treatment period to closely monitor therapy-induced
changes in angiogenesis parameters (Figure 1A).
In accordance with previous reports [20,21], a rapid and signifi-
cant (P = .002) increase of plasma VEGF levels was observed in re-
sponse to the first bevacizumab administration, and VEGF values
remained elevated for the subsequent treatment period (Figure 1, B
and C ). The “feedback production” of VEGF is known as a pharma-
codynamic marker of bevacizumab therapy but does not counteract
VEGF inactivation by the antibody [20,22]. Because group 1 started
bevacizumab treatment with a delay of 6 weeks, the rise in VEGF
plasma concentration was not detected before time point 5 of blood
sampling. Correspondingly, a significant difference in VEGF blood
levels between treatment groups was observed for the blood collec-
tion time points 2, 3, and 4 (P = .042, P = .005, and P < .001) when
group 1 received single-agent gemcitabine.
To monitor tumor load in the course of neoadjuvant therapy,
the tumor marker CA 19-9 was evaluated. A significant decline in
CA 19-9 blood concentration (P = .006 for time points 1 and 8)
was evident on treatment (Figure 1D). No significant difference be-
tween groups was observed when evaluated for the entire study pe-
riod or for the first 6 weeks of gemcitabine therapy with or without
bevacizumab (Figure 1E).
The potential of VEGF and CA 19-9 to predict therapy response
or patient prognosis was further investigated. The baseline level or
increase of VEGF on bevacizumab treatment (as determined after
the first antibody administration or after completion of therapy)
did not correlate with patient response according to RECIST criteria.
Similarly, CA 19-9 pretreatment levels or therapy-associated changes
did not differ significantly between responders and nonresponders.
Furthermore, OS was not predicted by either parameter.
Gemcitabine Does Not Induce Significant EPC Mobilization
throughout Therapy
Since Shaked et al. [15] reported a rapid (4 hours) mobilization of
EPCs by paclitaxel as opposed to gemcitabine but did not investigate
later time points of therapy, we monitored EPC blood counts by flow
cytometry in 2-week intervals throughout neoadjuvant treatment
(Figure 2, A and B). When EPC levels of sampling time points 2
to 8 were compared with baseline values, no significant change in
EPC counts was observed. Furthermore, EPC measurements were
assigned to two categories based on gemcitabine administration to
more appropriately evaluate chemotherapy-induced effects. Median
EPC values obtained by blood sampling 1 week after gemcitabine
administration (time points 2, 4, 6, and 8) ranged at 1.5 cells/
500,000 leukocytes and did not differ significantly from EPC counts
recorded before therapy or after chemotherapy breaks (time points 1,
3, 5, and 7) with a median value of 2.0 cells/500,000 leukocytes.
Importantly, EPC fluctuations were comparable between treatment
groups and did not seem to be affected by the onset of anti-VEGF
therapy (Figure 2B).
SDF-1α Release Is Counteracted by Thrombocytopenia
Platelet-released SDF-1α has been proposed to be the major in-
ducer of EPC mobilization in response to chemotherapy [15]. There-
fore, we investigated circulating SDF-1α values and their relation to
platelet counts in seven patients of treatment group 1 and of group 2
during neoadjuvant gemcitabine treatment. Irrespective of treatment
group, chemotherapy did not result in a significant elevation of SDF-
1α plasma levels (median value of 1654 pg/ml after chemotherapy at
time points 2, 4, 6, and 8 versus median value of 1729 pg/ml before
therapy or after therapy breaks at time points 1, 3, 5, and 7). In con-
trast, SDF-1α levels showed a tendency to decline after gemcitabine
administration (Figure 2C ). Similarly, platelet counts were found to
exhibit a pronounced decrease in response to gemcitabine treatment
and to recover in intermitting periods (Figure 2D), with median val-
ues ranging at 171 G/L after chemotherapy versus 334 G/L before
therapy or after therapy breaks (P < .001). To assess the potential
impact of thrombocytopenia on the availability of circulating SDF-
1α, plasma values of SDF-1α were adjusted to standard platelet
counts of 300 G/L (Figure 2E ). On the basis of the “normalized”
SDF-1α levels, a significant induction of circulating SDF-1α values
by gemcitabine treatment became apparent, which was followed by a
decline to baseline levels in intermission periods (P < .001; value of
2879 pg/ml after chemotherapy versus value of 1085 pg/ml before
therapy or after therapy breaks). Of note, no significant impact of
bevacizumab addition and no difference between treatment groups
were observed for SDF-1α or platelet fluctuations (data not shown).
Gemcitabine Reduces Circulating Monocytes and
Proangiogenic TEMs
Because proangiogenic cell populations distinct from EPCs, such
as TEMs, were also shown to be induced by paclitaxel as opposed to
gemcitabine and to be target of anti-VEGF therapy [15], we evalu-
ated circulating TEM, total monocyte, and leukocyte counts during
neoadjuvant treatment of pancreatic cancer patients. In accordance
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with the time course of platelets, leukocytes (Figure 3A), monocytes
(Figure 3B), and TEMs (Figure 3C ) also fluctuated corresponding to
the chemotherapy schedule, which was reflected in a significant cor-
relation (P ≤ .004) between these cell populations and was indicative
of a general myelosuppression.
Compared with the overall leukocyte population, the suppressive
effect on blood monocytes was highly pronounced. Monocyte counts
differed significantly (P < .001) between time points after gemcitabine
administration (median = 4.5 × 105 CD14+ cells/ml blood) and time
points before therapy or after recovery periods (median = 8.9 × 105
CD14+ cells/ml blood). Similarly, TEM levels displayed a recurrent
“drop-and-rebound” pattern and varied significantly with gemcitabine
treatment schedule (P = .002; median value of 4273 CD14+ Tie2+
CD16+ cells/ml blood after chemotherapy versus median value of
8865 CD14+ Tie2+ CD16+ cells/ml blood before therapy or after ther-
apy breaks). Comparable results were obtained for study arms 1 and 2,
Figure 1. Blood levels of VEGF and CA 19-9 in pancreatic cancer patients undergoing neoadjuvant therapy. (A) Schematic representation
of study design and blood sampling time points 1 to 8: The onset of bevacizumab administration is indicated by dashed and solid arrows
for treatment groups 1 and 2, respectively. Plasma concentrations of VEGF (B, C) and CA 19-9 (D, E) according to blood collection
schedule are illustrated by box plot for all patients n = 20 (B, D) or for the individual treatment groups n1 = 9 and n2 = 11 (C, E).
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and no significant impact of bevacizumab administration was recorded
(data not shown).
Platelet-Derived Angiogenesis Inhibitor TSP-1 Is Reduced by
Gemcitabine Therapy
Beside their central role in SDF-1α release and EPC recruitment,
platelets abundantly store angiogenic factors [23,24]. As we had ob-
served an intense reduction of platelet counts during chemotherapy,
it was of interest to investigate whether thrombocytopenia was as-
sociated with a decrease in circulating angiogenic factors known to
be released by platelets. In addition to VEGF (Figure 1, B and C ),
bFGF and PD-ECGF as well as TSP-1 were evaluated in patient
plasma during neoadjuvant treatment (Figure 4, A–C ). The pro-
angiogenic molecules VEGF, bFGF, and PD-ECGF did not fluctuate
in accordance with platelet counts. In contrast to VEGF, the plasma
concentrations of bFGF and PD-ECGF did not vary with treatment
group, that is, showed no bevacizumab-associated regulation. Of
interest, blood levels of the potent antiangiogenic protein TSP-1 dis-
played a “drop-and-rebound” pattern reminiscent of platelet fluctua-
tions (Figure 4A), which was reflected in a significant correlation
between parameters (P < .001, k = 0.399). Furthermore, TSP-1 levels
differed significantly with treatment schedule (P = .001; median
TSP-1 value of 43 ng/ml after chemotherapy versus median value
of 65 ng/ml before therapy or after therapy breaks).
Discussion
The combination of chemotherapy with bevacizumab has shown vary-
ing outcome, ranging from a highly significant increase in OS to a
complete lack of patient benefit when compared with chemotherapy
without VEGF blockade [25]. This discrepancy may relate to tumor
entity or combination of regimens. Indeed, increasing evidence argues
in favor of the latter hypothesis. The currently conducted “RIBBON-
2” trial on locally recurrent or metastatic breast cancer compares the
efficacy of bevacizumab therapy in combination with distinct chemo-
therapeutic agents. Preliminary data presented at the 2010 ASCO
Meeting [26] suggest that breast cancer patients receiving taxane or
capecitabine profit from bevacizumab augmentation, whereas the
Figure 2. Effect of neoadjuvant treatment on EPC counts, blood platelets, and SDF-1α plasma levels of pancreatic cancer patients.
Fluctuations of EPCs (CD34+ CD133+ blood cells) are presented by box plot for the entire study collective n = 15 (A) or separately
for treatment arms n1 = 6 and n2 = 9 (B). C, D, and E illustrate the time course of SDF-1α (n = 7), blood platelets (n = 19), and
SDF-1α levels normalized to a platelet count of 300 G/L (n = 7) irrespective of treatment group.
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combination with gemcitabine seems unfavorable. This finding is
supported by the observation that bevacizumab addition to gem-
citabine therapy failed to achieve improvements for pancreatic cancer
patients [9].
Shaked et al. [15] provided an intriguing explanation for the clin-
ical results. They demonstrated in a mouse model that distinct ther-
apeutics such as taxanes and 5-FU induce the rapid mobilization of
proangiogenic cell populations (EPCs, TEMs) by platelet release of
SDF-1α, whereas other regimens like gemcitabine or doxorubicin do
not elicit this effect. Furthermore, they showed that VEGF blockade
could counteract the proangiogenic cell recruitment thereby leading to
selective treatment benefits for combinations with “mobilizing” agents.
In contrast, “nonmobilizing” chemotherapeutics like gemcitabine lack
synergism with anti-VEGF agents. We now propose that the distinct
myelosuppressive properties of “nonmobilizing” regimens determine
this lack of synergism.
In a clinical study on neoadjuvant chemotherapy, we investigated
alterations in blood parameters of pancreatic cancer patients receiving
continuous gemcitabine therapy and three or six doses of bevacizumab.
The marked increase in VEGF plasma levels on bevacizumab admin-
istration documented the selective systemic response to VEGF inhibi-
tion, which has previously been reported and does not interfere with
complete VEGF blockade [20,22]. However, the pharmacodynamic
changes in circulating VEGF did not correlate with enhanced tu-
mor marker decline (comparing treatment periods with and without
bevacizumab supplementation) or with patient response and survival.
Thus, the prolonged treatment with bevacizumab did not improve
patient benefit in this clinical setting.
Importantly, we observed an intense and recurring myelosuppressive
effect of gemcitabine treatment, which was reflected in blood compo-
nents known to mediate proangiogenic cell mobilization. Platelet
Figure 4. Effect of chemotherapy on circulating proangiogenic and
antiangiogenic factors. The plasma levels of antiangiogenic TSP-1
(A, n = 20), proangiogenic PD-ECGF (B, n = 20), and bFGF (C, n =
6) were determined by ELISA and are presented by box plot in rela-
tion to blood sampling time points, irrespective of treatment group.
Figure 3. Changes in leukocyte, monocyte, and TEM counts dur-
ing pancreatic cancer therapy. Total populations of blood leuko-
cytes (A, n = 17), CD14+ monocytes (B, n = 7), and the subset
of CD14+ CD16+ Tie2+ TEMs (C, n = 7) were monitored in patient
blood by flow cytometry. Data are illustrated by box plot irrespec-
tive of treatment group.
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counts were severely reduced in immediate response to gemcitabine
administration and recovered in therapy breaks, thus yielding a char-
acteristic “drop-and-rebound” pattern. In accordance with platelets be-
ing the major source for circulating SDF-1α, plasma levels of SDF-1α
showed a tendency to decrease on gemcitabine treatment. Of interest,
when SDF-1α values were adjusted for platelet counts, a remarkable
and consistent increase in response to chemotherapy was observed,
reminiscent of the SDF-1α release induced by “mobilizing” agents
[15]. This suggests that gemcitabine may in fact trigger SDF-1α secre-
tion by platelets resulting in an increased ratio of circulating SDF-1α
to platelet counts. However, thrombocytopenia limits the available
pool of SDF-1α, which results in a net decrease of SDF-1α blood lev-
els. With SDF-1α being the central stimulus for chemotherapy-
induced EPC mobilization [15], thrombocytopenia (and additional
myelosuppression) may therefore prevent EPC recruitment. Corre-
spondingly, we did not detect significant EPC induction during neo-
adjuvant treatment with gemcitabine.
Furthermore, myelosuppression was detectable in a remarkable de-
crease of monocytes and circulating proangiogenic TEMs. Because
anti-VEGF therapy was also shown to block TEM recruitment by
“mobilizing” agents [15], TEM reduction by myelosuppression may
further account for the lack of synergism between “nonmobilizing”
therapeutics and bevacizumab. Figure 5 illustrates the accordance of
parameters involved in proangiogenic cell mobilization, which are
affected by the myelosuppressive activity of gemcitabine.
In contrast to the pronounced effect on thrombocyte and mono-
cyte counts, gemcitabine showed only a moderate suppression of
total leukocytes in our study. Considering that neutrophils consti-
tute most blood leukocytes, suppression of platelet and monocyte
populations rather than neutropenia may thus be characteristic for
“nonmobilizing” therapeutics. In support of this notion, the taxanes
paclitaxel and docetaxel were shown to induce severe neutropenia but
little toxicity to blood platelets [27] and have demonstrated “mobi-
lizing” potential resulting in synergy with bevacizumab therapy [15].
Interestingly, two studies with cancer patients report on stable or
even increasing monocyte counts in taxane combination therapies
with substantial neutropenia [28,29]. Similarly, the “mobilizing” agent
5-FU does not affect monocyte counts in chemoradiotherapy [30]
despite its potential to reduce blood neutrophils [31]. Thus, we pro-
pose that the distinct capacity of chemotherapeutics to selectively or
concomitantly induce thrombocyte and monocyte toxicity may limit
the efficacy of bevacizumab combination therapy, although neutro-
penia seems of minor importance in this context. (Of note, lympho-
cyte toxicity has not been investigated by us.)
Because the clinical assessment of treatment-related toxicities gen-
erally do not report on monocyte counts, we used the incidence of
grades 3 and 4 thrombocytopenia as a surrogate marker to identify mye-
losuppressive chemotherapies unlikely to synergize with bevacizumab
therapy. It should be noted that we specifically focused on phase 3
trials that directly compared the impact of chemotherapeutic agents
within the same study [32–35]. Strikingly, the regimens that had
been identified by Shaked et al. to induce proangiogenic cell recruit-
ment (e.g., taxanes and 5-FU) were less commonly associated with
platelet reduction compared with the “nonmobilizing” agents gem-
citabine and doxorubicin (Table 1). Moreover, the comparison of
two studies with advanced NSCLC patients receiving bevacizumab
in combination with distinct chemotherapies revealed remarkable
associations between efficacy and thrombocytopenia [4,36]. Patients
were treated with platin-based chemotherapy plus paclitaxel or gem-
citabine in the absence or presence of bevacizumab (at 15 mg/kg). The
combination of “mobilizing” paclitaxel and bevacizumab increased
median PFS by 1.7 months compared with chemotherapy without
VEGF blockade. In contrast, the combination of “nonmobilizing”
gemcitabine plus bevacizumab prolonged PFS only marginally by
0.4 months. Furthermore, OS was only prolonged when bevacizumab
was applied in combination with paclitaxel [4,37]. Of note, grades 3
and 4 thrombocytopenia were recorded in 1.6% of paclitaxel-treated
patients as opposed to 23% of patients receiving gemcitabine.
Because platelets are known to contribute to angiogenesis by path-
ways distinct from SDF-1α release and EPC mobilization [23], it
was of interest to evaluate if thrombocytopenia would translate into
Figure 5. Concurrent parameter fluctuations in accordance with
chemotherapy schedule. Median values of platelets, TSP-1 (multi-
plied by 5), SDF-1α (divided by 7), and TEMs (divided by 20) as es-
tablished throughout neoadjuvant cancer therapy are depicted in
relation to gemcitabine administration. Therapy breaks (preceding
blood withdrawal) are indicated by arrowheads.
Table 1. Incidence of Grades 3 and 4 Thrombocytopenia Associated with Distinct Chemotherapies.
Burris et al. [32] Chan et al. [33] Joensuu et al. [34] Albain et al. [35]
Disease Advanced pancreatic cancer Metastatic breast cancer Advanced breast cancer Metastatic breast cancer
No. patients 126 326 237 529
Chemotherapy 5-FU Gemcitabine Docetaxel Doxorubicin Docetaxel Docetaxel alternating
gemcitabine
Paclitaxel Paclitaxel +
gemcitabine
Incidence of thrombocytopenia
≥ grade 3
1.6% 9.7% 1.3%* 7.5%* 0% 4.1% 0% 6.1%
*Only grade 4 events were reported.
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fluctuations of angiogenic factors that are comprised in platelets. In
this context, proangiogenic bFGF and PD-ECGF were found to be
largely unaffected by the “drop-and-rebound” changes in platelet
counts. Also, VEGF induction by bevacizumab seemed to be inde-
pendent of thrombocytopenia. This suggests that the circulating pro-
angiogenic factors investigated (VEGF, bFGF, PD-ECGF) were not
predominantly platelet-derived but may have been released by tumor
or host cell sources other than platelets. In contrast, a highly significant
correlation with platelet counts was observed for the antiangiogenic
protein TSP-1 (Figure 5), which is in line with our previous investi-
gation suggesting platelets as the major determinant for circulating
TSP-1 [38]. The potent angiogenesis inhibitor TSP-1 is increasingly
recognized to be a critical mediator of anticancer effects. Expression
and release of TSP-1 by platelets direct the host response to suppress
tumor growth through inhibiting tumor angiogenesis [24,39]. Fur-
thermore, TSP-1 has been shown to mediate the antiangiogenic effects
of metronomic chemotherapy [40]. On the basis of this knowledge,
we propose that the repetitive reduction of TSP-1 by thrombocyto-
penia represents a proangiogenic side effect of gemcitabine therapy
not influenced by bevacizumab, which may further limit the benefits
of VEGF blockade in combination with gemcitabine.
In conclusion, chemotherapeutic regimens that repeatedly pre-
sented unfavorable in combination with bevacizumab share the com-
mon feature of thrombocytopenia. Although there may be additional
obstacles to antiangiogenic treatment, myelosuppression of thrombo-
cytes and monocytes seems to effectively prevent the mobilization of
proangiogenic cell populations (EPCs and TEMs), which are the
target of anti-VEGF therapy and the point of synergy in successful
combinatorial regimens. Furthermore, the pronounced thrombocyto-
penia results in a selective loss of the angiogenesis inhibitor TSP-1,
which may further explain the disappointing results of myelosuppres-
sive chemotherapeutics in combination with antiangiogenic treatment.
Thus, determining the myelosuppressive effect of chemotherapy on
thrombocyte and monocyte counts during the active phase of treat-
ment may help to select or exclude agents for combination therapy.
Future clinical trials will have to elucidate if bevacizumab combined
with chemotherapies of low myelosuppressive activity is able to im-
prove patient outcome for tumor types like pancreatic cancer, which
have previously not profited from anti-VEGF therapy.
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